Research · Sep 3, 2026
[WAT] Waters Corporation Thesis 2026: Becton Dickinson Biosciences Deal Tests Mass Spectrometry Recovery
Waters Corporation (NYSE: WAT) FY2025 revenue ~$2.95-3.05B (+0-3%) with adj. EPS ~$11.50-13.00 reflecting continued post-2024 biopharma R&D spending compression similar to TECH + CRL + selected July 2024 announced Becton Dickinson Biosciences + Diagnostic Solutions ~$17.5B acquisition pending close 2025-2026 (transformative) + selected ~50%+ recurring revenue resilience + selected category-leading LC/MS franchise under continued CEO Udit Batra (~5-year tenure since September 2020). Leading global analytical instruments firm focused on liquid chromatography (LC) + mass spectrometry (MS) instruments + selected thermal analysis + rheology. Founded 1958 by James Logan Waters in Framingham Massachusetts (~67-year heritage; selected initial focus on selected liquid chromatography innovation); IPO 1995 NYSE (selected post-IPO ~50x+ stock appreciation through 2021 peak albeit with selected post-2022 cyclical compression). Headquartered in Milford Massachusetts; ~7,800+ employees globally with ~$2.95-3.05B revenue. Three reporting end-markets: Pharmaceutical ~60% revenue ($1.8B — selected biopharma R&D + QC analytical instruments via ACQUITY UPLC + Xevo mass spectrometry + selected analytical chemistry workflows for selected pharma quality control; ~30%+ global LC/MS market share leadership), Industrial ~25% ($750M — selected chemical + materials + food/environmental + post-2008 TA Instruments thermal analysis + rheology), Academic & Government ~15% ($450M — selected research universities + selected government labs). ~50%+ revenue recurring (consumables + service; selected high-margin recurring revenue ~50%+ aftermarket gross margin). July 2024 Becton Dickinson Biosciences + Diagnostic Solutions ~$17.5B acquisition: selected announced largest transformative transaction; BD Biosciences contribution ~$2B+ revenue (flow cytometry + molecular diagnostics + microbiology) + BD Diagnostic Solutions ~$1B+ revenue; combined entity ~$5B+ revenue + ~10,000+ combined employees post-close; ~$200-300M expected cost synergies; pending close 2025-2026 (regulatory approval + SEC filings + debt financing); ~$10-12B all-cash deal financed via debt + combined balance sheet leverage post-close ~3.5-4x net debt/EBITDA. Pharmaceutical segment cycle: post-2024 biopharma R&D spending compression similar to TECH + CRL; FY2026 expected Pharmaceutical toward $1.85-1.95B (+3-7%) on biopharma R&D stabilization + obesity/GLP-1 + AI drug discovery driving new instrument demand. CEO Udit Batra since September 2020 (succeeded Christopher O'Connell CEO 2015-September 2020 retired; Batra ex-Merck KGaA Life Science CEO 2015-2020 + ex-various life sciences ~25-year career; Indian-American; selected appointed to lead post-2020 strategic refresh + July 2024 Becton Dickinson Biosciences deal). Capital return: $0 dividend (no dividend); modest buybacks $100-300M FY2025 (selected post-BD deal capital allocation prioritization); investment-grade A3/A- credit ratings (will become Baa1/BBB+ post-BD close). FY2026 thesis: BD deal closing + Pharmaceutical recovery + recurring revenue stability + Industrial cycle. Risks: BD deal regulatory pushback, major biopharma R&D cycle deterioration, Agilent + Thermo Fisher competitive substitution, post-BD deleveraging stress.